Back to Science

Scientific Publications

A comprehensive list of peer-reviewed manuscripts detailing our research on the PREP-PP2A axis, related pathologies, and novel therapeutic compounds.

PDNeuroinflammation

Novel PREP ligand, HUP-46, ameliorates behavioral deficits in an alpha-synuclein based Parkinson's disease model

Kilpeläinen et al.
Experimental Neurology
2026
TBI

A prolyl oligopeptidase ligand blocks memory deficit in a repeated mild traumatic brain injury model

Myöhänen T, et al.
Experimental Neurology
2025
Chemistry

5-Aminothiazoles Reveal a New Ligand-Binding Site on Prolyl Oligopeptidase Which is Important for Modulation of Its Protein–Protein Interaction-Derived Functions

Pätsi et al.
J Med Chem
2024
Tauopathy

A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy

Eteläinen et al.
Sci Transl Med
2023
ChemistryPD

Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease

Kilpeläinen et al.
J Med Chem
2023
MoA

Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A

Svarcbahs et al.
Pharmacological Research
2020
MoA

New tricks of prolyl oligopeptidase inhibitors – A common drug therapy for several neurodegenerative diseases

Svarcbahs et al.
Biochemical Pharmacology
2019
Tauopathy

Protein phosphatase 2A dysfunction in Alzheimer's disease

Sontag & Sontag
Front Mol Neurosci
2014
Pathology

Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases

Hannula et al.
Neuroscience
2013
MoA

Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders

Männistö et al.
Drug News Perspect
2007